TB-500 and the thymosin beta-4 wound studies
The short fragment carries an actin-binding region. The muscle and skin findings discussed here used the full-length protein.
Fragment identity: Ac-LKKTETQ
TB-500 is the synthetic Ac-LKKTETQ fragment: Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln-OH. Its seven amino acids correspond to residues 17–23 of the 43-amino-acid thymosin beta-4 protein. The fragment weighs approximately 889 daltons; the full protein approximately 4,963 daltons. Most published efficacy findings attributed to TB-500 come from that larger molecule.
The review of thymosin beta-4 biology covers cell migration, angiogenesis, anti-inflammatory activity and reduced scar-forming myofibroblasts across several models. I mark the full protein’s name mentally each time the result travels into a discussion of the fragment. Those experiments give the short molecule a reason to be investigated. Its performance still needs direct testing.
Cell migration across gaps
Actin helps cells change shape and move. Structural work using an actin-bound gelsolin–thymosin beta-4 hybrid showed how thymosin beta-4-derived regions cap the ends of an actin monomer, preventing it from joining a filament. The mechanism concerns a pool of actin units available for changing the cell’s internal structure.
In the rat skin-wound experiment, full-length thymosin beta-4 improved surface coverage, contraction, collagen deposition and angiogenesis. That is a more substantial set of observations than simply saying a cell moved. I wonder how faithfully cell migration predicts organized tissue, while the jump from full protein to short fragment remains an experimental question.
Human tolerability of full-length thymosin beta-4
The randomized, placebo-controlled Phase 1 study in 40 healthy volunteers administered full-length thymosin beta-4 intravenously. It reported infrequent mild-to-moderate adverse events, no dose-limiting toxicities and no serious adverse events. It also characterized pharmacokinetics. The trial’s molecule and route are essential to that result.
No completed controlled human trial has established the TB-500 fragment’s efficacy or safety for an indication. The 2026 review of unapproved musculoskeletal peptides places the favorable animal findings beside scarce rigorous human safety data and potential for serious harm. I cannot extend the full protein’s tolerability finding to an unregulated fragment preparation.
Uneven responses and safety questions
The rat embolic-stroke study of full-length thymosin beta-4 found improved neurological function at 2 and 12 mg/kg, while 18 mg/kg gave no significant benefit. Those are doses used in male Wistar rats. They demonstrate an uneven response in that model and provide no validated human regimen for TB-500.
Thymosin beta-4’s role in cell movement and blood-vessel formation also raises a theoretical tumor-progression concern, discussed in the biological review. Human risk for the short fragment remains unquantified. TB-500 has no FDA approval and is WADA-prohibited in and out of competition. Its inclusion in Wolverine or KLOW adds an untested combination to the fragment’s existing evidence gap.